The Readout Loud

241

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

356: An AI experiment at the FDA & Novo trailing in the obesity drug race
Jun 5, 2025 – 33:05
355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview
May 29, 2025 – 36:55
354: Uncertainty in CRISPR world and the start of more M&A
May 22, 2025 – 41:30
353: Trump's drug-pricing plan and a potential Theranos 2.0
May 15, 2025 – 25:47
352: A firebrand takes oversight of vaccines, gene therapies
May 8, 2025 – 26:28
351: It's gonna be May (in biotech)
May 1, 2025 – 35:19
350: Pharma tariffs, and a 'sunshine day' for biotech stocks
Apr 24, 2025 – 31:40
349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding
Apr 10, 2025 – 40:55
348: Cuts, ousters and drama at the FDA
Apr 3, 2025 – 31:10
347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
Mar 27, 2025 – 31:25
346: Zealand's obesity strategy and Immunovant's curious development plan
Mar 20, 2025 – 42:34
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
Mar 13, 2025 – 31:00
344: Trump's FDA commissioner nominee takes the hot seat
Mar 6, 2025 – 25:51
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
Feb 27, 2025 – 32:01
342: FDA cuts, zombie biotechs, and too much weight loss?
Feb 20, 2025 – 41:00
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
Feb 13, 2025 – 26:39
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
Feb 6, 2025 – 34:45
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Jan 30, 2025 – 34:29
338: Chinese biotechs, a WHO departure, and post-JPM thoughts
Jan 23, 2025 – 33:09
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
Jan 15, 2025 – 58:47
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
Jan 9, 2025 – 33:21
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
Dec 19, 2024 – 33:43
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Dec 12, 2024 – 34:30
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
Dec 5, 2024 – 27:55
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Nov 21, 2024 – 35:08
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
Nov 14, 2024 – 30:16
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
Nov 7, 2024 – 39:22
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
Oct 31, 2024 – 28:25
328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
Oct 24, 2024 – 33:46
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
Oct 17, 2024 – 34:19
326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI
Oct 10, 2024 – 40:08
325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO
Oct 3, 2024 – 32:48
From Tradeoffs: Race to the Bottom
Sep 28, 2024 – 28:08
324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
Sep 26, 2024 – 32:02
323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates
Sep 19, 2024 – 35:21
322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
Sep 12, 2024 – 32:57
321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
Sep 5, 2024 – 35:18
320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
Aug 29, 2024 – 37:34
From "Say More": What Happens When AI Decides Your Medical Coverage
Aug 23, 2024 – 22:42
319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides
Aug 22, 2024 – 34:07
318: Drug pricing drops & psychedelics under fire
Aug 15, 2024 – 21:16
317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
Aug 8, 2024 – 28:52
316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates
Aug 1, 2024 – 34:15
315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves
Jul 25, 2024 – 32:46
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
Jul 18, 2024 – 33:02
313: Biotech layoffs, founder-focused VC, & a big pharma exit
Jul 11, 2024 – 34:52
312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
Jun 27, 2024 – 28:33
311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review
Jun 20, 2024 – 34:10
310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)
Jun 13, 2024 – 38:46
309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
Jun 6, 2024 – 29:34